Eagle Pharmaceuticals Granted Patent for PEMFEXY®
24 oct. 2023 08h40 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted...
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
23 oct. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic...
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting
04 oct. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial...
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
19 sept. 2023 16h05 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
11 sept. 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease ---- The...
Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference
30 août 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has been selected to present a platform...
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
29 août 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the dosing regimen for all fulvestrant patients and provide the opportunity for...
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
22 août 2023 16h05 HE
|
Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian...
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
17 août 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.701 ---- Reflects strength of Eagle’s business and...
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
08 août 2023 06h50 HE
|
Eagle Pharmaceuticals, Inc.
• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income...